Related references
Note: Only part of the references are listed.Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms
Cecile Saint-Martin et al.
BLOOD (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
Animesh Pardanani et al.
STEM CELLS (2007)
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur et al.
CANCER (2007)
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia
Ayalew Tefferi et al.
BLOOD (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis:: chronology of clonal emergence and changes in mutant allele burden over time
Terra L. Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
R Kralovics et al.
EXPERIMENTAL HEMATOLOGY (2002)
Share Paper
